Sign in Subscribe
Cancer research

Breakthrough in Lung Cancer Immunotherapy: New Molecular Markers and Prognostic Signature Unveiled

Strategic Insights

— 1 min read

Scientists at China Three Gorges University have made a significant breakthrough in lung cancer research, unveiling new molecular markers and a prognostic signature that could improve immunotherapy responses and clinical outcomes in patients with lung adenocarcinoma. According to the study published in PeerJ, the researchers identified 10 machine learning algorithms and a new computational framework to determine prognostic genes. These genes were combined to develop an immune prognostic signature (IMMPS) using the stepCox and Ridge methods. The expression of the signature genes was validated by quantitative real-time PCR (qRT-PCR).

Key Takeaways:

  • The study was designed to screen molecular markers related to tumor-infiltrating cells in lung adenocarcinoma (LUAD) to improve immunotherapy response during LUAD therapy.
  • The ConsensusClusterPlus method was used to cluster immune molecular subtypes of LUAD, and immune cell infiltration and immunotherapeutic potential in each subtype were evaluated employing single-sample gene set enrichment analysis (ssGSEA), Tumor Immune Dysfunction and Exclusion (TIDE), and Immunophenoscore (IPS).
  • Immune-related co-expression modules were classified by weighted gene co-expression network analysis (WGCNA) analysis.
  • The sequencing data of immune-related genes were comprehensively analyzed by introducing a new computational framework and 10 machine learning algorithms to determine prognostic genes.
  • The IMMPS could serve as a promising tool for improving the clinical outcome of patients suffering from LUAD.
  • Dr. Zhen Chen and Dr. Yongjun Zhang were the lead researchers on this project, with Dr. Chen as the corresponding author.

Statistics:

  • The study used a total of 10 machine learning algorithms to determine prognostic genes.
  • The IMMPS was developed using the stepCox and Ridge methods.
  • The expression of the signature genes was validated by qRT-PCR.
  • The study found that the immune-activated subgroup C2 was more likely to benefit from immunotherapy (p < 0.05).
  • The results of this study contribute to a better understanding of the immunological characteristics of lung adenocarcinoma.

Sources:

  • Development of an immune-related gene signature applying Ridge method for improving immunotherapy responses and clinical outcomes in lung adenocarcinoma. PeerJ, 2025,13():e19121. (PeerJ - https://peerj.com/)
  • NewsRx. Reports Summarize Lung Cancer Research from China Three Gorges University (Development of an immune-related gene signature applying Ridge method for improving immunotherapy responses and clinical outcomes in lung adenocarcinoma). Immunotherapy Weekly. May 28, 2025; p 2824.

Read more